Senhwa Biosciences, Inc. (6492)’in fiyatı nedir?

Senhwa Biosciences, Inc. (6492)’in fiyatı $1.11’dir

Senhwa Biosciences, Inc. (6492)’in piyasa değeri nedir?

Senhwa Biosciences, Inc. (6492)’in piyasa değeri $100.55M’dir.

Senhwa Biosciences, Inc. (6492) Faaliyet Marjı

Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its compound CX-5461 is undergoing various investigations, including a Phase I, open-label study assessing dose escalation, safety, pharmacokinetics, and pharmacodynamics of its intravenous administration in individuals with advanced blood cancers. CX-5461 is also in a Phase I trial for solid cancerous growths, as well as a Phase Ib expansion study focusing on solid tumors characterized by BRCA2 and/or PALB2 genetic mutations. Furthermore, CX-5461 is being evaluated in a Phase I trial alongside pidnarulex and talazoparib for patients battling metastatic castration-resistant prostate cancer. Beyond CX-5461, Senhwa is also developing several variations of CX-4945. CX-4945-CCA is participating in a Phase I/II clinical investigation, combined with gemcitabine, for treating cholangiocarcinoma. CX-4945-BCC is the subject of a Phase I, multi-center, open-label study, examining its safety and pharmacodynamic profile when administered orally twice daily to patients with advanced basal cell carcinoma. The company's CX-4945-MB compound is being explored in a Phase I/II and surgical study, led by a pediatric brain tumor consortium, for the management of recurrent SHH medulloblastoma. Lastly, CX-4945-AV06 is currently in a Phase II, double-blind, randomized, controlled study, designed to evaluate its safety and effectiveness in hospitalized adults afflicted with COVID-19.

Yıl	Faaliyet Marjı	Değiştir
Sağlanan tarihler için yeterli veri yok.

Yıl

Faaliyet Marjı

Değiştir

Sağlanan tarihler için yeterli veri yok.

Şirket	Faaliyet Marjı	Faaliyet Marjı Farkı	Ülke
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
Moderna, Inc. MRNA.US	-149.01%	-	US
CSL Limited CSL.AX	25.72%	-	AU
Lonza Group AG LONN.SW	0.00%	-	CH

Şirket

Faaliyet Marjı

Faaliyet Marjı Farkı

Ülke